



Multiple Comparison Procedures for Exponential Mean Lifetimes Compared with Several Controls

Shu-Fei Wu

Article

Department of Statistics, Tamkang University, Taipei 251301, Taiwan; 100665@mail.tku.edu.tw

Abstract: Under heteroscedasticity, we propose one-stage multiple comparison procedures for several treatment groups compared with several control groups in terms of exponential mean lifetimes. The simultaneous confidence intervals including one-sided and two-sided confidence intervals for the difference between the mean lifetime from the *i*-th treatment group and the mean lifetime from the *j*-th control group are developed in this research. The required critical values are obtained and tabulated for the practical use of users. The experimenters can use these simultaneous confidence intervals or worse than several controls under a specified confidence level. Finally, one example of comparing the mean duration of remission using four drugs for treating leukemia is used for the aims of illustrations.

Keywords: one-stage procedure; multiple comparison with the control; multiple comparison with several controls; exponential distribution

1. Introduction

Our research is related to the field of ranking and selection. For normal distributions, Bechhofer [1] and Gupta [2] are the pioneers in this field. Instead of normal distributions, exponential distributions are widely used to model the lifetimes of products. For exponential lifetime distributions, $k (\geq 2)$ independent treatment groups and l control groups are considered. Let X_{i1}, \dots, X_{im} be the random sample of size *m* from the *i*-th treatment group π_i , I = 1, ..., k, where π_i follows a two-parameter exponential distribution denoted by $E(\theta_i, \sigma_i)$, I = 1, ..., k. The parameters $\theta_1, \dots, \theta_k$ are the unknown location parameters (also known as the guaranteed time in reliability and engineering) and the parameters $\sigma_1, \dots, \sigma_k$ are the unknown and unequal scale parameters. Likewise, let $X_{i1}^*, \dots, X_{im}^*$ be the random sample of size *m* from the *j*-th control group $\pi_i^*, j = 1, \dots, l$, where π_i^* follows a two-parameter exponential distribution denoted by $E(\eta_i, \xi_i)$, j = 1, ..., *l*. The parameters η_1, \dots, η_l are the unknown location parameters and parameters ξ_1, \dots, ξ_l are the unknown and unequal scale parameters. Furthermore, the mean lifetime for the *i*-th treatment group is $\mu_i = \theta_i + \sigma_i$, I = 1, ..., k and the mean lifetime for the *j*-th control group is $\mu_j^* = \eta_j + \xi_j$, j = 1, ..., l. When scale parameters for exponential distributions are unknown and possibly unequal, Lam and Ng [3] proposed the design-oriented two-stage multiple comparisons with the control. Please see Lam and Ng [3] for the detailed introduction for the two-stage procedures. The disadvantage for the two-stage procedure is that the required sample size for the second stage may be large. To remedy this problem, the one-stage sampling procedure addressed above can be considered instead. Based on the one-stage sample from k populations, Wu et al. [4] developed the multiple

comparison procedures for exponential location parameters with the control when scale

Citation: Wu, S.-F. Multiple Comparison Procedures for Exponential Mean Lifetimes Compared with Several Controls. *Mathematics* **2022**, *10*, 609. https://doi.org/10.3390/ math10040609

Academic Editors: Francisco Ureña and Leonid Piterbarg

Received: 23 December 2021 Accepted: 15 February 2022 Published: 16 February 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). parameters are unknown and unequal. Instead of comparing with the control, Wu [5] proposed one-stage multiple comparisons with the average for exponential location parameters. Maurya [6] investigated the one-stage multiple comparisons with more than one control under heteroscedasticity. Maurya [7] proposed another one-stage multiple comparisons with a control under heteroscedasticity. Instead of comparing the location parameters for exponential distributions, the one-stage multiple comparisons with the average in terms of mean lifetimes are proposed by Wu [8]. Unlike the multiple comparison procedure with the control based on mean lifetimes in Wu [8], the aim and the novelty of this paper is to compare several treatment populations with more than one control populations based on the mean lifetimes. The research methodologies are addressed in Section 2 by using the techniques in Lam's research ([9,10]). The research results in Wu [8] can be treated as a special case of our proposed method in this paper when the number of control populations l = 1. Therefore, this paper has more general applications compared with the results in Wu [8]. In order to illustrate our proposed simultaneous confidence intervals in Section 2, we use an example of comparing two treatment drugs with two control drugs for treating leukemia in Section 3. In this example, each drug group consists of 20 patients and the dataset for each group passed the fitness test for exponential distribution by the use of the Gini test (Gail and Gastwirth [11]). In Lawless [12], they conducted a likelihood ratio asymptotic chi-squared test for the homogeneity of scale parameters and the results revealed that the scale parameters for four exponential distributions are significantly different. In Section 4, the conclusions related to our research methods are made.

2. Comparing with Several Controls for Exponential Mean Lifetimes

For the one-stage sample X_{i1}, \dots, X_{im} of size *m* from the *i*-th treatment group, we let $Y_i = \min(X_{i1}, \dots, X_{im})$ and $S_i = \sum_{j=1}^m (X_{ij} - Y_i)/(m-1)$, $I = 1, \dots, k$. Likewise, for the one-stage sample $X_{j1}^*, \dots, X_{jm}^*$ of size *m* from the *j*-th control group, we let $Y_j^* = \min(X_{j1}^*, \dots, X_{jm}^*)$ and $S_j^* = \sum_{i=1}^m (X_{ji}^* - Y_j^*)/(m-1)$, $j = 1, \dots, l$.

Before we start to construct the simultaneous confidence interval (SCI) for $\mu_i - \mu_j^*$, I = 1, ..., k, j = 1, ..., l, we need to consider the following random variables:

$$G_{i} = \left(-mS_{i}/\sigma_{i} + m - m(Y_{i} - \theta_{i})/\sigma_{i}\right)/(S_{i}/\sigma_{i}), I = 1, ..., k \text{ and}$$

$$G_{j}^{*} = \left(-mS_{j}^{*}/\xi_{j} + m - m(Y_{j}^{*} - \eta_{j})/\xi_{j}\right)/(S_{j}^{*}/\xi_{j}), j = 1, ..., l.$$

From Roussas [13], they indicated that $Q_i = 2(m-1)S_i / \sigma_i \sim \chi^2_{2m-2}$ and $Q_j^* = 2(m-1)S_j^* / \xi \sim \chi^2_{2m-2}$, where χ^2_{2m-2} represents a chi-squared distribution with 2m - 2 degrees of freedom (df). Furthermore, $E_i = m(Y_i - \theta_i) / \sigma_i \sim Exp(1)$ and $E_j^* = m(Y_j^* - \eta_j) / \xi_j \sim Exp(1)$, where Exp(1) represents a standard exponential distribution. In addition, the random variables $E_i, Q_i, i = 1, ..., k$ and $E_j^*, Q_j^*, j = 1, ..., l$ are stochastically independent.

In terms of $E_i, Q_i, i = 1, ..., k$ and $E_j^*, Q_j^*, j = 1, ..., l$, the random variables $G_i, I = 1, ..., k$ and $G_j^*, j = 1, ..., l$ can be rewritten as follows:

$$G_{i} = \frac{-mS_{i}/\sigma_{i} + m - m(Y_{i} - \theta_{i})/\sigma_{i}}{S_{i}/\sigma_{i}} = \frac{-2m(m-1)S_{i}/\sigma_{i} + 2(m-1)(m-m(Y_{i} - \theta_{i})/\sigma_{i})}{2(m-1)S_{i}/\sigma_{i}}$$
$$= -m + \frac{2(m-1)(m-E_{i})}{Q_{i}}$$

and

$$G_{j}^{*} = \frac{-m S_{j}^{*} / \xi_{j} + m - m(Y_{j}^{*} - \eta_{j}) / \xi_{j}}{S_{j}^{*} / \xi_{j}} = -m + \frac{2(m-1)(m - E_{j}^{*})}{Q_{j}^{*}}.$$

Once the independent random variables $E_i \sim Exp(1)$ and $Q_i \sim \chi^2_{2m-2}$ are generated, the random variable G_i can be thus generated, I = 1, ..., k. Likewise, once the independent random variables $E_i \sim Exp(1)$ and $Q_i \sim \chi^2_{2m-2}$, are generated, the random variable G_j^* can be generated, j = 1, ..., l.

Now we can propose the one-stage multiple comparison procedures for exponential mean lifetimes with several controls denoted by $\mu_i - \mu_j^*$, I = 1, ..., k, j = 1, ..., l as follows:

Theorem 1. For a given 0 < P < 1, let $\widetilde{c} = \max_{i=1,\dots,k, j=1,\dots,l} \left(\frac{S_i}{m}, \frac{S_j^*}{m}\right)$,

$$G_{i} = \left(-mS_{i}/\sigma_{i} + m - m(Y_{i} - \theta_{i})/\sigma_{i}\right)/(S_{i}/\sigma_{i}), I = 1, ..., k \text{ and}$$

$$G_{j}^{*} = \left(-mS_{j}^{*}/\xi_{j} + m - m(Y_{j}^{*} - \eta_{j})/\xi_{j}\right)/(S_{j}^{*}/\xi_{j}), j = 1, ..., l.$$

We have the following results:

(a) If \widetilde{S}_U is the 100*P*-th percentile of the distribution of $\max(-G_j^*, G_i, G_i - G_j^*, i = 1, \dots, k, j = 1, \dots, l)$, then we have

$$P(\mu_i - \mu_j^* \le Y_i + S_i - Y_j^* - S_j^* + \widetilde{c} \widetilde{s}_U, i = 1, \dots, k, j = 1, \dots, l) \ge P.$$

Thus, $(-\infty, Y_i + S_i - Y_j^* - S_j^* + \widetilde{cS}_U)$ is a set of upper confidence intervals for $\mu_i - \mu_j^*$ with confidence coefficient *P*, *I* = 1, ..., *k*, *j* = 1, ..., *l*.

(b) If \widetilde{S}_L is the 100*P*-th percentile of the distribution of $\max(-G_i, G_j^*, G_j^* - G_i, i = 1, \dots, k, j = 1, \dots, l)$, then we have

$$\mathbf{P}(\mu_{i} - \mu_{j}^{*} \ge Y_{i} + S_{i} - Y_{j}^{*} - S_{j}^{*} - \widetilde{c}\widetilde{s}_{L}, i = 1, \dots, k, j = 1, \dots, l) \ge P.$$

Thus, $(Y_i + S_i - Y_j^* - S_j^* - \widetilde{cs}_L, \infty)$ is a set of lower confidence intervals for $\mu_i - \mu_j^*$ with confidence coefficient *P*, *I* = 1, ..., *k*, *j* = 1, ..., *l*.

(c) If \widetilde{S}_t is the 100*P*-th percentile of the distribution of $\max(|G_i|, |G_j^*|, |G_j^* - G_i|, i = 1, \dots, k, j = 1, \dots, l)$, then we have

$$P(Y_i + S_i - Y_j^* - S_j^* - \widetilde{c}\widetilde{s}_i \le \mu_i - \mu_j^* \le Y_i + S_i - Y_j^* - S_j^* + \widetilde{c}\widetilde{s}_i, i = 1, \dots, k, j = 1, \dots, l) \ge P$$

Thus, $(Y_i + S_i - Y_j^* - S_j^* \pm \widetilde{c}\widetilde{s}_i)$ is a set of simultaneous two-sided confidence

intervals for $\mu_i - \mu_j^*$ with confidence coefficient *P*, *I* = 1, ..., *k*, *j* = 1, ..., *l*.

The technique given in Lam ([9,10]) is described in the following lemma:

Lemma 1. If X and Y are two random variables, a and b are two positive constants, then $[aX \ge bY - d \max(a,b)] \supseteq [X \ge -d, Y \le d \text{ and } X \ge Y - d].$

The proof of Lemma 1 is given in Lam [1] and it is briefly given in the section of Appendix A. Using the technique in Lemma 1, the proof of Theorem 1 is also given in Appendix A.

Since the critical values \widetilde{S}_U , \widetilde{S}_L and \widetilde{S}_t in Theorem 1 are difficult to obtain, the Monte Carlo simulation method is used to find the critical values and the algorithm to obtain these critical values is given as follows:

Step 1: Generate *k* independent random variables $E_i \sim Exp(1)$ and *l* independent random variables $E_j^* \sim Exp(1)$. Generate another *k* independent random variables Q_i

~ $\chi^2_{2(m-1)}$ and *l* independent random variables $Q_j^* \sim \chi^2_{2(m-1)}$.

Then, the k + l independent random variables:

$$G_{i} = -m + 2(m-1)(m-E_{i})/Q_{i} \quad I = 1, ..., k \text{ and}$$

$$G_{j}^{*} = -m + 2(m-1)(m-E_{j}^{*})/Q_{j}^{*}, \quad j = 1, ..., l \text{ can be generated.}$$

Step 2: The values of $\max(-G_j^*, G_i, G_i - G_j^*, i = 1, \dots, k, j = 1, \dots, l)$,

$$\max(-G_i, G_j^*, G_j^* - G_i, \quad , i = 1, \dots, k, \ j = 1, \dots, l) \quad \text{and}$$
$$\max(|G_i|, |G_i^*|, |G_i^* - G_i|, i = 1, \dots, k, \ j = 1, \dots, l) \quad \text{can be computed.}$$

Step 3: Repeat Step 1 and Step 2 100,000 times. Then, the critical values \tilde{S}_U , \tilde{S}_L and \tilde{S}_t can be obtained as the 100*P*-th empirical percentiles of

 $\max(-G_i^*, G_i, G_i - G_i^*, i = 1, \dots, k, j = 1, \dots, l),$

$$\max(-G_i, G_j^*, G_j^* - G_i, , i = 1, \dots, k, j = 1, \dots, l)$$
 and

$$\max(|G_i|, |G_i^*|, |G_i^* - G_i|, i = 1, \dots, k, j = 1, \dots, l)$$
 respectively

The approximate critical values \tilde{S}_U , \tilde{S}_L , and \tilde{S}_t under (k,l) = (2,2), (2,3), (2,4), (3,2), (3,3), (4,2), m = 2(1)10(5)30 and P = 0.90, 0.95, and 0.975 are listed in Table 1. From

Table 1, it can be seen that the approximate critical values \tilde{S}_U , \tilde{S}_L , and \tilde{S}_t are increasing while k + l is increasing for any given P and m or while P is increasing for any given k, l, and m. Let L_1 be the length of the two-sided confidence intervals for $\mu_i - \mu_j^*$, I = 1, ..., k, j = 1, ..., l for the one-stage procedure, then we have $L_1 = 2 \widetilde{CS}_t$. From this equation, we can see that the larger the k + l, the larger the value of \tilde{S}_t and then the larger confidence length of L_1 for any given P and m. Likewise, we can also see that when P increases, the confidence length increases for any given k, l, and m.

Table 1. Critical values of \widetilde{S}_U , \widetilde{S}_L , and \widetilde{S}_t for P = 0.90, 0.95, and 0.975.

			<i>P</i> = 0.90			<i>P</i> = 0.95			<i>P</i> = 0.975		
k	1	m	\widetilde{s}_U	\widetilde{S}_L	\widetilde{S}_t	\widetilde{s}_U	\widetilde{S}_L	\widetilde{S}_t	\widetilde{s}_U	\widetilde{S}_L	\widetilde{S}_t
2	2	2	24.32	24.36	49.17	50.12	50.52	100.37	100.68	102.56	202.85
		3	11.13	11.13	16.84	17.06	17.06	25.14	25.35	25.26	36.73
		4	9.51	9.52	13.23	13.34	13.38	18.07	18.10	18.19	24.08
		5	9.18	9.20	12.27	12.33	12.39	16.01	16.03	16.10	20.43
		6	9.22	9.22	12.02	12.11	12.11	15.31	15.35	15.36	19.02
		7	9.40	9.42	12.06	12.14	12.13	15.04	15.08	15.09	18.33
		8	9.65	9.64	12.22	12.30	12.28	15.07	15.12	15.10	18.16
		9	9.90	9.93	12.44	12.48	12.53	15.19	15.22	15.23	18.09
		10	10.21	10.23	12.72	12.78	12.79	15.39	15.42	15.43	18.24
		15	11.67	11.68	14.23	14.29	14.28	16.85	16.87	16.87	19.47
		20	13.02	13.03	15.70	15.75	15.75	18.35	18.36	18.39	20.98
		25	14.28	14.30	17.10	17.13	17.17	19.84	19.84	19.88	22.46
		30	15.48	15.42	18.41	18.49	18.44	21.27	21.33	21.26	24.01
2	3	2	26.30	35.08	61.24	53.65	71.91	124.81	107.23	145.94	252.28
		3	11.65	14.09	19.30	17.70	21.30	28.67	26.07	31.42	41.94
		4	9.96	11.57	14.83	13.84	16.01	20.08	18.67	21.54	26.65
		5	9.61	10.90	13.55	12.82	14.44	17.52	16.54	18.52	22.18
		6	9.68	10.81	13.20	12.57	13.95	16.61	15.81	17.42	20.47
		7	9.90	10.89	13.15	12.63	13.78	16.27	15.62	16.92	19.65
		8	10.14	11.09	13.28	12.78	13.87	16.18	15.58	16.80	19.33
		9	10.43	11.34	13.48	13.01	14.03	16.29	15.75	16.85	19.31
		10	10.73	11.65	13.75	13.29	14.29	16.48	15.94	17.01	19.38
		15	12.31	13.10	15.28	14.91	15.75	17.91	17.49	18.36	20.55
		20	13.76	14.51	16.80	16.47	17.21	19.46	19.09	19.85	22.05
		25	15.13	15.86	18.29	17.95	18.71	21.01	20.64	21.40	23.68
		30	16.39	17.10	19.67	19.38	20.05	22.54	22.23	22.88	25.34
2	4	2	28.14	46.00	73.85	56.73	94.80	150.80	114.03	190.63	303.81
		3	12.08	16.69	21.52	18.19	25.01	31.74	26.67	36.62	46.28
		4	10.25	13.17	16.07	14.15	18.05	21.66	18.96	24.10	28.58
		5	9.90	12.25	14.59	13.12	16.04	18.75	16.84	20.46	23.57
		6	9.98	11.99	14.08	12.86	15.27	17.60	16.08	18.97	21.59
		7	10.19	11.99	13.97	12.92	15.01	17.15	15.88	18.29	20.70
		8	10.46	12.16	14.07	13.08	15.04	17.09	15.90	18.13	20.32
		9	10.76	12.41	14.28	13.36	15.18	17.15	16.05	18.12	20.18
		10	11.10	12.65	14.52	13.67	15.36	17.31	16.35	18.17	20.24
		15	12.76	14.13	16.05	15.33	16.78	18.70	17.88	19.42	21.38
		20	14.32	15.59	17.63	17.01	18.28	20.29	19.63	20.90	22.92

		25	15.70	16.96	19.13	18.51	19.76	21.87	21.22	22.45	24.51
		30	17.04	18.25	20.57	20.01	21.19	23.41	22.81	24.00	26.16
3	2	2	35.20	26.44	61.78	72.37	54.14	126.61	147.01	108.88	255.82
		3	14.11	11.73	19.34	21.36	17.76	28.75	31.50	26.19	41.94
		4	11.54	9.95	14.79	15.96	13.82	20.01	21.39	18.67	26.57
		5	10.90	9.62	13.56	14.44	12.82	17.54	18.57	16.52	22.21
		6	10.81	9.69	13.21	13.95	12.58	16.65	17.48	15.83	20.50
		7	10.88	9.87	13.15	13.79	12.61	16.25	16.93	15.60	19.68
		8	11.07	10.12	13.25	13.84	12.75	16.17	16.78	15.57	19.28
		9	11.36	10.43	13.50	14.09	13.02	16.32	16.93	15.71	19.29
		10	11.62	10.76	13.75	14.27	13.32	16.50	17.03	15.98	19.37
		15	13.09	12.30	15.25	15.71	14.87	17.89	18.35	17.46	20.53
		20	14.52	13.78	16.82	17.25	16.48	19.50	19.91	19.13	22.13
		25	15.85	15.14	18.28	18.67	17.98	21.02	21.37	20.70	23.69
		30	17.08	16.40	19.66	20.04	19.38	22.51	22.84	22.18	25.23
3	3	2	36.89	37.08	71.42	75.84	76.37	149.80	154.64	151.29	307.21
		3	14.75	14.65	20.62	21.62	21.84	30.33	32.03	32.58	45.30
		4	11.93	11.96	15.14	16.50	16.32	20.75	21.69	22.07	27.54
		5	11.34	11.33	13.72	14.91	14.92	17.98	18.98	19.23	22.82
		6	11.18	11.21	13.19	14.41	14.38	16.75	17.81	17.80	20.63
		7	11.35	11.39	13.09	14.23	14.33	16.23	17.41	17.31	19.67
		8	11.60	11.59	13.13	14.26	14.34	16.06	17.34	17.34	19.34
		9	11.89	11.84	13.27	14.63	14.63	16.24	17.43	17.37	19.13
		10	12.17	12.18	13.48	14.78	14.82	16.21	17.64	17.51	19.15
		15	13.70	13.81	14.79	16.35	16.33	17.44	19.08	18.86	20.20
		20	15.23	15.33	16.20	17.95	17.98	18.87	20.59	20.67	21.55
		25	16.74	16.71	17.60	19.39	19.54	20.19	22.18	22.23	23.09
		30	18.06	18.07	18.86	20.93	20.89	21.70	23.63	23.77	24.37
4	2	2	46.06	28.21	73.93	94.26	57.19	150.66	189.64	114.78	301.99
		3	16.63	12.08	21.46	24.99	18.16	31.72	36.63	26.62	46.31
		4	13.19	10.23	16.07	18.01	14.11	21.60	24.00	18.93	28.49
		5	12.26	9.90	14.59	16.05	13.08	18.77	20.50	16.83	23.66
		6	11.98	9.95	14.09	15.30	12.86	17.64	18.99	16.10	21.62
		7	12.02	10.19	14.01	15.06	12.92	17.21	18.36	15.92	20.74
		8	12.17	10.47	14.09	15.05	13.12	17.10	18.13	15.95	20.35
		9	12.37	10.78	14.25	15.14	13.38	17.13	18.06	16.11	20.19
		10	12.66	11.12	14.54	15.39	13.68	17.32	18.20	16.35	20.24
		15	14.12	12.75	16.04	16.76	15.31	18.67	19.39	17.90	21.32
		20	15.57	14.28	17.62	18.29	16.98	20.27	20.93	19.57	22.89
		25	16.96	15.69	19.14	19.79	18.53	21.89	22.52	21.22	24.55
		30	18.23	17.01	20.53	21.16	19.96	23.39	23.99	22.77	26.09

3. Example

From Wu et al. [4], data consisting of the duration of remission achieved by four drugs for treating leukemia are used to illustrate our proposed simultaneous confidence intervals in Theorem 1. The data are listed in Table 2. We regard drugs 1,2 as the treatment groups π_1, π_2 and drugs 3,4 as the control groups π_1^*, π_2^* .

Drug 1 (μ_1)	Drug 2 (μ_2)	Drug 3 (μ_1^*)	Drug 4 (μ_2^*)
1.034	2.214	4.158	5.115
2.344	4.976	4.025	4.498
1.266	8.154	5.170	4.617
1.563	2.686	11.909	4.651
1.169	2.271	4.912	4.533
4.118	3.139	4.629	4.513
1.013	2.214	3.955	7.641
1.509	4.480	6.735	5.971
1.109	8.847	3.140	12.130
1.965	2.239	12.446	4.699
5.136	3.473	8.777	4.914
1.533	2.761	6.321	17.169
1.716	2.833	3.256	5.497
2.778	2.381	8.250	11.332
2.546	3.548	3.759	18.922
2.626	2.414	5.205	13.712
3.413	2.832	3.071	6.309
1.929	5.551	3.147	10.086
2.061	3.376	9.773	9.293
2.951	2.968	10.218	11.787

Table 2. Data for the duration of remission by four drugs.

The longer mean duration of remission time (μ_i or μ_j^* , i = 1,2, j = 1,2) is desired for this example. Lawless [12] conducted the likelihood ratio asymptotic χ^2 test to show that there is a significant difference among the four scale parameters. Thus, the data analysis one-stage multiple comparison procedures with several controls $\mu_i - \mu_j^*$, i = 1,2, j = 1,2 in Theorem 1 for exponential mean lifetimes under heteroscedasticity can be applied. The required statistics and critical values of \widetilde{S}_U , \widetilde{S}_L , and \widetilde{S}_i for P = 0.90, 0.95, and 0.975 are summarized in Table 3.

Table 3. The required statistics and critical values.

Statistics	Drug 1	Drug 2	Statistics	Drug 3	Drug 4
Y_i	1.013	2.214	Y_j^*	3.071	4.498
S_i	1.238	1.530	S_{j}^{*}	3.233	4.075
\widetilde{c}	0.204				
	$Y_1 - Y_1^* +$	$Y_2 - Y_1^* +$			
	$S_1 - S_1^*$	$S_2 - S_1^*$			
	-4.053	-2.560			
	$Y_1 - Y_2^* +$	$Y_2 - Y_2^* +$			
	$S_1 - S_2^*$	$S_2 - S_2^*$			
	-6.322	-4.829			
Р	\widetilde{s}_{U}	\widetilde{S}_L	\widetilde{S}_t		

0.900	13.02	13.03	15.70
0.950	15.75	15.75	18.35
0.975	18.36	18.39	20.98

Applying parts (a) and (b) of Theorem 1, we can find the upper and lower confidence bounds for $\mu_i - \mu_j^*$, i = 1,2, j = 1,2 with confidence coefficients 0.90, 0.95, and 0.975 given in Table 4. With respect to the upper confidence bounds, drug 1 is selected in a subset of worse than several controls (drug 3 and 4) and drugs 1 and 2 are selected in a subset of worse than the control (drug 3) with the probability of correct selection being at least 0.90, 0.95, and 0.975 in terms of mean lifetimes since their one-sided confidence intervals do not contain zero.

Table 4. The upper confidence bounds and lower confidence bounds under P = 0.90, 0.95, 0.975.

Parameter	$(-\infty, Y_i + S_i - Y_j^* - S_j^* + \widetilde{c}\widetilde{s}_U), (Y_i + S_i - Y_j^* - S_j^* - \widetilde{c}\widetilde{s}_L, \infty)$					
	90%	95%	97.5%			
1. $\mu_1 - \mu_1^*$	(-∞,-1.397), (-6.711,∞)	(-∞,-0.840), (-7.266,∞)	(-∞,-0.320), (-7.805,∞)			
2. $\mu_1 - \mu_2^*$	(-∞,-3.666), (-8.980,∞)	(-∞,-3.109), (-9.535,∞)	(-∞,-2.589), (-10.07,∞)			
3. $\mu_2 - \mu_1^*$	(−∞,0.096), (−5.218,∞)	(-∞,0.653), (-5.773,∞)	(−∞,1.173), (−6.312,∞)			
4. $\mu_2 - \mu_2^*$	(-∞,-2.173), (-1.616,∞)	(-∞,-1.616), (-8.042,∞)	(-∞,-1.096), (-8.581,∞)			

Applying part (c) of Theorem 1, we can find the two-sided confidence bounds for $\mu_i - \mu_j^*$, i = 1,2, j = 1,2 with confidence coefficients 0.90, 0.95, and 0.975 listed in Table 5. For confidence coefficients 0.90, 0.95, and 0.975, we can conclude that drug 1 is worse than several controls (drugs 3 and 4) and drug 2 is worse than drug 4 since both bounds of the two-sided confidence intervals for these two drugs are negative. Furthermore, drug 2 is not significantly different from drug 3 in terms of mean remission times.

Parameter	$(Y_i + S_i - Y_j^* - S_j^* - \widetilde{c}\widetilde{s}_t, Y_i + S_i - Y_j^* - S_j^* + \widetilde{c}\widetilde{s}_t)$					
	90%	95%	97.5%			
1. $\mu_{\rm l} - \mu_{\rm l}^{*}$	(-7.256, -0.850)	(-7.800, -0.310)	(-8.333, 0.227)			
2. $\mu_1 - \mu_2^*$	(-9.525, -3.119)	(-10.07, -2.579)	(-10.60, -2.042)			
3. $\mu_2 - \mu_1^*$	(-5.763, 0.643)	(-6.303, 1.183)	(-6.840, 1.720)			
4. $\mu_2 - \mu_2^*$	(-8.032, -1.626)	(-8.572, -1.086)	(-9.109, -0.549)			

Table 5. The two-sided confidence intervals under P=0.90, 0.95, 0.975.

4. Conclusions

From the critical values in Table 1 and the equation of $L_1 = 2 \widetilde{CS}_t$, it is found that the length of SCI is getting wider when we compare more populations for fixed *P* and *m*.

In practical applications, we may have several control populations instead of one control population. Applying Lam's [9,10] technique, we propose a multiple comparison procedure with several controls for exponential mean lifetimes under heteroscedasticity. In addition, the critical values for (k,l) = (2,2), (2,3), (2,4), (3,2), (3,3), (4,2), m = 2(1)10(5)30 and P * = 0.90, 0.95, and 0.975 are provided for the use of this investigation problem in

Table 1. Finally, we use one example to illustrate the practical use of our proposed procedures in Theorem 1. The multiple comparison procedure with one control for exponential mean lifetimes in Wu [8] is only a special case of our new procedure in Theorem 1 of this research when l = 1. Therefore, the results in this paper have more general methods in many fields of applications.

Funding: This research was funded by the Ministry of Science and Technology, Taiwan, MOST 108-2118-M-032-001 and MOST 109-2118-M-032-001-MY2 and the APC was funded by MOST 109-2118-M-032-001-MY2.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data available in a publicly accessible repository. The data presented in this study are openly available in Wu et al. [4].

Conflicts of Interest: The author declares no conflict of interest.

Appendix A

Proof of Lemma 1.

Consider the following three cases: Case 1: For $b \ge a$, $[X \ge Y - d \text{ and } Y \le d]$ implies $aX \ge a(Y - d) \ge b(Y - d) \ge bY - d \max(a, b)$. Case 2: For b < a and $Y \le 0$, $[X \ge -d]$ implies $aX \ge -ad \ge bY - d \max(a, b)$. Case 3: For b < a and Y > 0, $[X \ge Y - d]$ implies $aX \ge a(Y - d) \ge bY - d \max(a, b)$. The proof is established. \Box

Proof of Theorem 1.

For (a), we have

$$P(\mu_{i} - \mu_{j}^{*} \leq Y_{i} + S_{i} - Y_{j}^{*} - S_{j}^{*} + \widetilde{c}\widetilde{s}_{U}, i = 1, \dots, k, j = 1, \dots, l)$$

$$= P(\theta_{i} + \sigma_{i} - \eta_{j} - \xi_{j} \leq Y_{i} + S_{i} - Y_{j}^{*} - S_{j}^{*} + \widetilde{c}\widetilde{s}_{U}, i = 1, \dots, k, j = 1, \dots, l)$$

$$= P(-S_{i} + \sigma_{i} + \theta_{i} - Y_{i} \leq -S_{j}^{*} + \eta_{j} + \xi_{j} - Y_{j}^{*} + \widetilde{c}\widetilde{s}_{U}, i = 1, \dots, k, j = 1, \dots, l)$$

$$= P\left(\frac{S_{i}}{m}\frac{\sigma_{i}}{S_{i}}\frac{m(-S_{i} + \sigma_{i} + \theta_{i} - Y_{i})}{\sigma_{i}} \leq \frac{S_{j}^{*}}{m}\frac{\eta_{j}}{S_{j}^{*}}\frac{m(-S_{j}^{*} + \eta_{j} + \xi_{j} - Y_{j}^{*})}{\eta_{j}} + \widetilde{c}\widetilde{s}_{U}^{*}\right)$$

$$= P\left(\frac{S_{j}^{*}}{m}G_{j}^{*} \geq \frac{S_{i}}{m}G_{i} - \widetilde{c}\widetilde{s}_{U}, i = 1, \dots, k, j = 1, \dots, l\right)$$

$$\geq P\left(G_{j}^{*} \geq -\widetilde{s}_{U}, G_{i} \leq \widetilde{s}_{U}, G_{j}^{*} \geq G_{i} - \widetilde{s}_{U}, i = 1, \dots, k, j = 1, \dots, l\right)$$

$$= P\left(-G_{j}^{*} \leq \widetilde{s}_{U}, G_{i} \leq s_{U}^{*}, G_{i} - G_{k} \leq \widetilde{s}_{U}, i = 1, \dots, k, j = 1, \dots, l\right)$$

$$= P\left(\max(-G_{j}^{*}, G_{i}, G_{i} - G_{j}^{*}, i = 1, \dots, k, j = 1, \dots, l\right) \leq \widetilde{s}_{U}\right) = P$$

Satisfying the above equation, the value of \tilde{S}_U is determined as the 100*P*-th percentile of the distribution of $\max(-G_j^*, G_i, G_i - G_j^*, i = 1, \dots, k, j = 1, \dots, l)$ and the proof is thus established.

For (b), we have

$$\begin{split} & \mathsf{P}(\mu_{i} - \mu_{j}^{*} \geq Y_{i} + S_{i} - Y_{j}^{*} - S_{j}^{*} - \widetilde{c}\widetilde{s}_{L}, i = 1, \cdots, k, j = 1, \dots, l) \\ & \mathsf{P}\left(\theta_{i} + \sigma_{i} - \eta_{j} - \xi_{j} \geq Y_{i} + S_{i} - Y_{j}^{*} - S_{j}^{*} + \widetilde{c}\widetilde{s}_{L}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & = \mathsf{P}\left(-S_{i} + \sigma_{i} + \theta_{i} - Y_{i} \geq -S_{j}^{*} + \eta_{j} + \xi_{j} - Y_{j}^{*} + \widetilde{c}\widetilde{s}_{L}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & = \mathsf{P}\left(\frac{S_{i}}{m} \frac{\sigma_{i}}{S_{i}} \frac{m(-S_{i} + \sigma_{i} + \theta_{i} - Y_{i})}{\sigma_{i}} \geq \frac{S_{j}^{*}}{m} \frac{\eta_{j}}{S_{j}^{*}} \frac{m(-S_{j}^{*} + \eta_{j} + \xi_{j} - Y_{j}^{*})}{\eta_{j}} + \widetilde{c}\widetilde{s}_{L} \\ &, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & = \mathsf{P}\left(\frac{S_{i}}{m}G_{i} \geq \frac{S_{j}^{*}}{m}G_{j}^{*} - \widetilde{c}\widetilde{s}_{L}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & \geq \mathsf{E}_{S_{1}, \cdots, S_{k}} \mathsf{P}\left(\frac{S_{i}}{m}G_{i} \geq \frac{S_{j}^{*}}{m}G_{j}^{*} - \max(\frac{S_{i}}{m}, \frac{S_{j}^{*}}{m})\widetilde{s}_{L}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & \geq \mathsf{P}\left(G_{i} \geq -\widetilde{s}_{L}, G_{j}^{*} \leq \widetilde{s}_{L}, G_{i} \geq G_{j}^{*} - \widetilde{s}_{L}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & \geq \mathsf{P}\left(-G_{i} \leq \widetilde{s}_{L}, G_{j}^{*} \leq \widetilde{s}_{L}, G_{j}^{*} - G_{i} \leq \widetilde{s}_{L}, i = 1, \dots, k, j = 1, \dots, l\right) \\ & = \mathsf{P}\left(\max(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \cdots, k, j = 1, \dots, l\right) \leq \widetilde{s}_{L}\right) = \mathsf{P}\left(\mathsf{Max}\left(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \cdots, k, j = 1, \dots, l\right)\right) \\ & = \mathsf{P}\left(\mathsf{max}\left(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \cdots, k, j = 1, \dots, l\right)\right) \\ & = \mathsf{P}\left(\mathsf{max}\left(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & = \mathsf{P}\left(\mathsf{max}\left(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & = \mathsf{P}\left(\mathsf{max}\left(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & \mathsf{P}\left(\mathsf{Max}\left(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & \mathsf{P}\left(\mathsf{Max}\left(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & \mathsf{P}\left(\mathsf{Max}\left(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \cdots, k, j = 1, \dots, l\right) \\ & \mathsf{P}\left(\mathsf{Max}\left(-G_{i}, G_{j}^{*}, G_{j}^{*} - G_{i}, i = 1, \dots, k, j = 1, \dots, l\right) \\ & \mathsf{P}\left(\mathsf{Max}\left(-G_{i}, G_{j}^{*}, G_{i}^{*} - G_{i}, i = 1, \dots, k, j = 1, \dots, l\right) \\ & \mathsf{P}\left(\mathsf{Max}\left(-G_{i}, G_{i}^{*}, G_{i}^{*} - G_{i}, i = 1, \dots$$

Satisfying the above equation, the value of \widetilde{S}_L is determined as the 100*P*-th percentile of the distribution of $\max(-G_i, G_j^*, G_j^* - G_i, i = 1, \dots, k, j = 1, \dots, l)$ and the proof is thus established.

For (c), combining (a) and (b), we have

$$\begin{split} & \mathsf{P}(Y_{i} + S_{i} - Y_{j}^{*} - S_{j}^{*} - \widetilde{c}\widetilde{s}_{t} \leq \mu_{i} - \mu_{j}^{*} \leq Y_{i} + S_{i} - Y_{j}^{*} - S_{j}^{*} + \widetilde{c}\widetilde{s}_{t} , i = 1, \cdots, k, j = 1, \dots, l) \\ &= \mathsf{P}\left(Y_{i} + S_{i} - Y_{j}^{*} - S_{j}^{*} - \widetilde{c}\widetilde{s}_{t} \leq \theta_{i} + \sigma_{i} - \eta_{j} - \xi_{j} \leq Y_{i} + S_{i} - Y_{j}^{*} - S_{j}^{*} + \widetilde{c}\widetilde{s}_{t} , \\ &, i = 1, \cdots, k, j = 1, \dots, l) \\ &= \mathsf{E}_{S_{1}, \cdots, S_{k}} \mathsf{P}\left(-G_{i} \leq \widetilde{s}_{t} , G_{j}^{*} \leq \widetilde{s}_{t} , G_{j}^{*} - G_{i} \leq \widetilde{s}_{t} \cap G_{j}^{*} \leq \widetilde{s}_{t} , G_{i} \leq \widetilde{s}_{t} , G_{i} - G_{j}^{*} \leq \widetilde{s}_{t} , i = 1, \cdots, k, j = 1, \dots, l) \\ &\geq \mathsf{P}\left(\mathsf{max}(|G_{i}|, |, G_{j}^{*}|, |, G_{j}^{*} - G_{i}|, i = 1, \cdots, k, j = 1, \dots, l) \leq \widetilde{s}_{t} \right) = P. \end{split}$$

Satisfying the above equation, the value of \widetilde{S}_i is determined as the 100*P*-th percentile of the distribution of $\max(|G_i|, |G_j^*|, |G_j^* - G_i|, i = 1, \dots, k, j = 1, \dots, l)$ and the proof is thus established. \Box

References

- 1. Bechhofer, R.E. A single sample multiple decision procedure for ranking means of normal populations with known variances. *Ann. Math. Stat.* **1954**, *25*, 16–39.
- Gupta, S.S. On a Decision Rule for a Problem in Ranking Means. Doctoral Dissertation, Mimeograph Series No. 150, Institute of Statistics, University of North Carolina, Chapel Hill, NC, USA, 1956.
- 3. Lam, K.; Ng, C.K. Two-stage procedures for comparing several exponential populations with a control when the scale parameters are unknown and unequal. *Seq. Anal.* **1990**, *9*, 151–164.
- Wu, S.F.; Lin, Y.P.; Yu, Y.R. One-stage multiple comparisons with the control for exponential location parameters under heteroscedasticity. *Comput. Stat. Data Anal.* 2010, 54, 1372–1380.
- 5. Wu, S.F. New one-stage multiple comparisons procedures with the average for exponential location parameters under heteroscedasticity. *J. Stat. Comput. Simul.* **2016**, *86*, 2740–2748.
- 6. Maurya, V.; Goyal, A.; Gill, A.N. Multiple comparisons with more than one control for exponential location parameters under heteroscedasticity. *Commun. Stat. Simul. Comput.* **2011**, *40*, 621–644.
- Maurya, V.; Gill, A.N.; Singh, P. Multiple comparisons with a control for exponential location parameters under heteroscedasticity. J. Appl. Stat. 2013, 40, 1817–1830.
- 8. Wu, S.F. One stage multiple comparisons of k-1 treatment mean lifetimes with the control for exponential distributions under heteroscedasticity. *Commun. Stat. Simul. Comput.* **2018**, 47, 2968–2978.
- Lam, K. Subset Selection of Normal Populations under Heteroscedasticity. IPASRAS-II: Proceedings and Discussions of the Second International Conference on Inference Procedures Associated with Statistal Ranking and Selection on the Frontiers of Modern Statistical Inference Procedures, II; ACM: New York, NY, USA, 1992; pp. 307–344.
- 10. Lam, K. An improved two-stage selection procedure. Commun. Stat. Simul. Comput. 1988, 17, 995–1006.
- 11. Gail, M.H.; Gastwirth, J.L. A scale-free goodness-of-fit Test for the Exponential Distribution Based on the Gini Statistic. J. R. Stat. Soc. Ser. B 1978, 40, 350–357.
- 12. Lawless, J.F. Statistical Models and Methods for Lifetime Data; Wiley: New York, NY, USA, 2003.
- 13. Roussas, G.G. A Course in Mathematical Statistics; Academic Press: San Diego, CA, USA, 1997.